Joel Eichmann is a life scientist with a background in bioprocess engineering, manufacturing, and synthetic biology. Before founding Green Elephant Biotech, he worked several years in the pharmaceutical industry in vaccine manufacturing and tech transfer projects. Now at Green Elephant Biotech he is leading the development of new products and acts as a linker between business development and R&D. He is also passionate about building a greener future for the pharmaceutical industry and helping manufacturers and researchers to reduce their environmental impact.

Diego is a Quality Operations and Business Principal Consultant with 27+ years of experience primarily in the Pharmaceuticals and Medical Devices Industries. He received first-class honors degree cum laude in Pharmaceutical Chemistry (CTF) and degree as a Pharmacist. Diego is a Qualified Person (QP) and a Senior International Auditor. He has a senior expertise in QA, GMP Compliance, FDA-readiness, Quality Systems and Operations, Warehousing and Distribution Practices (GDPs), Business Development. Diego is highly pragmatic, hands-on, change-oriented, and open to different company cultures

Dr. Sofia Venceslau is passioned about biochemistry and microbial organisms, with strong experience in USP and DSP of microbial systems and with over 20 publications in the field. Sofia joined GenIbet Biopharmeuticals, now ReciBioPharm, in 2019 where she is involved in an end-to-end solution to clients starting on business development, monitoring process development activities, responsible for the process technology transfer, scaling up and implementation of good manufacturing practices, assisting the success of the client´s project from the bench to clinical trials (phase 1 to 3). The portfolio includes manufacturing processes of different areas (protein vaccines, virus oncolytic vaccines, mRNA, DNA, live microbial products, etc) using different systems (bacteria, yeast, mammalian and insect cells, or in vitro systems).

Dale is a postdoctoral research fellow working in Professor Qasim Rafiq’s Cell and Gene Therapy Bioprocessing Group at University College London (UCL). His current project is focused on establishing scalable adeno-associated viral vector manufacturing processes, which is undertaken as part of the UCL-Cytiva Centre of Excellence. Previously, Dale completed his engineering doctorate (EngD) focused on establishing a continuous lentiviral vector manufacturing process in collaboration with Cytiva at UCL.   

Rob is one of three Managing Partners who run the Dark Horse Consulting Group practice (the other two being DHC’s Founder and CEO, Anthony Davies and DHC’s COO, Katey Spink). Rob joined DHC in early 2019 as a Principal on what was then a much smaller consulting team. His expertise ranged from manufacturing to process development to regulatory, as well as project/program management, market research, and due diligence/business strategy. During his tenure, the UK-based team grew rapidly (from two individuals to thirteen as of 2022) and in 2021, Rob became General Manager of the UK office and European team, aka DHC Europe, Ltd.

Bernd is very passionate about providing new and improved treatment options to patients in need. 

He has profound experience in the field of CAR-T therapy development and the commercialization of CAR-T cells. He most recently served as Head Customer Operations for cell & gene therapies at Novartis and was a member of the European cell & gene leadership team launching and commercializing Kymriah®, the first FDA-approved CAR-T cell product. Prior to that, Bernd was leading the cell therapies strategy development for Europe shaping the design of the commercial model for CAR-T provision. 

He helped to bring to market multiple new therapies during his extensive 20-years experience working in Lifesciences in pharma and biotech. He holds a Ph.D. in natural sciences from the ETH Zurich, Switzerland.